Department of Surgery, National Taiwan University Hospital
7, Chung-Shan S. Rd, Taipei 10002, Taiwan., Taiwan, 10002
NCT Number: NCT01423864
Acute respiratory distress syndrome (ARDS) in combination with multi-organ dysfunction syndrome (MODS) is a life-threatening condition, particularly when treatment modalities such as extracorporeal membrane oxygenation (ECMO) and catecholamine administration have failed to treat the severe condition. In this study, the investigators report patients who responded to intrapleural steroid instillation (IPSI) while being unresponsive to conventional treatment (use of intravenous steroids, nitric oxide inhalation, high-frequency oscillatory ventilation, or ECMO) for treatment of critical illnesses such as ARDS in combination with MODS.
Looking for future studies?
Notify Me16 year–87 year
All sexes
Interventional
Phase 2
7, Chung-Shan S. Rd, Taipei 10002, Taiwan., Taiwan, 10002
Acute respiratory distress syndrome (ARDS) with multi-organ dysfunction syndrome (MODS) are common debilitating postoperative complications, which also result from shock and trauma. However, despite the use of ECMO, mortality rate among hypoxia patients remains high in such critical care conditions. Corticosteroid therapy inhibits ongoing inflammation and abnormal deposition of collagen. However, intravenous administration of corticosteroids may be harmful because it may increase the risk of associated neuromyopathy in critically ill patients. Although intrapleural instillation of steroids has been employed in several pleural diseases,little is known about the therapeutic effects of this treatment method on ARDS in combination with MODS. Therefore, in the present pilot study, the investigators hypothesized that timely initiation of intrapleural steroid instillation (IPSI) will positively influence ventilation in and survival of patients with ARDS in combination with MODS.
The investigators conducted a retrospective study on ninety-two of the 467 ECMOs performed between 2005 and 2009 were on ARDS patients. Analyses of gas exchange, tidal volumes, airway pressures, respiratory frequency, and vasopressor and sedation requirements were performed before and after intervention.
The indication for IPSI was unresponsive severe ARDS in combination with MODS when all the other treatment modalities such as intravenous steroid administration, nitric oxide inhalation, high-frequency oscillatory ventilation, or ECMO performed within 2 days were unsuccessful.
An experienced team performed thoracic catheterization of the patients under ultrasound evaluation. Patients with severe pleural adhesion were considered unsuitable for IPSI. The dosage of the intrapleural steroid was determined on the basis of the chest radiographic examination, inspired oxygen concentration, and positive end-expiratory pressure (PEEP) of the ventilator.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
Other names: Solu-Cortef
Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
Time frame: 2005~2009 (up to 4 years)
Comparing the difference between two groups about the survival ratio of discharge from the hospital
Time frame: 12 weeks
complication of the interventional treatment will be followed for the duration of hospital stay
Time frame: up to 12 weeks
the therapeutic effects in the improvement of tidal volumes, followed for the duration of ventilator usage
Time frame: up to 12 weeks
the therapeutic effects in the improvement of oxygenation, followed for the duration of hospital stay
National Taiwan University Hospital
Other
Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome
Acronym: IP steroid
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07369206
Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07025096
Acute Respiratory Distress Syndrome (ARDS), Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06697717
Acute Respiratory Distress Syndrome (ARDS), Cardiovascular Diseases
Wuhan, Hubei, China
View Trial DetailsNCT06272942
Acute Respiratory Distress Syndrome (ARDS), Lung Diseases
Whippany, New Jersey, United States
View Trial Details